Related Experiment Video
Updated: Jul 12, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Anticoagulant blood factor deficiencies (protein C)
1Synthesizer Inc, Ellicott City, MD, USA.
Advances in Experimental Medicine and Biology
|August 31, 2007
Summary
Hidden blood conditions like Protein C deficiency can cause dangerous clots. This study proposes low-cost purification of Protein C to enable widespread screening and prophylactic treatment for coagulation disorders.
Area of Science:
- Biochemistry
- Hematology
- Medical Diagnostics
Background:
- Anticoagulant proteins (Protein C, Protein S, Antithrombin III) are vital for hemostasis.
- Deficiencies or Factor V Leiden can lead to thrombosis (e.g., deep vein thrombosis, pulmonary emboli).
- Current screening for these hidden conditions is limited, necessitating improved diagnostic and therapeutic approaches.
Purpose of the Study:
- To develop a cost-effective method for producing Zymogen Protein C.
- To enable widespread screening for hereditary anticoagulant deficiencies in adolescents.
- To explore prophylactic treatments for coagulation disorders.
Main Methods:
- Purification of Zymogen Protein C from Cohn Fraction IV-1 of blood plasma.
- Utilizing Immobilized Metal Affinity Chromatography (IMAC) for separation.
- Overcoming challenges posed by homologous Vitamin K-dependent proteins.
Main Results:
- Established a method for low-cost Zymogen Protein C production.
- Demonstrated the feasibility of using IMAC for separating similar proteins.
- Aimed to create a more accessible therapeutic agent.
Conclusions:
- Low-cost Protein C production is achievable through IMAC.
- This advancement could facilitate early detection and prophylactic treatment of coagulation disorders.
- Screening children aged 12-14 for deficiencies is proposed to prevent serious health issues.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...